Thus, targeting the classical SMAD or TAK pathways, or influencing SMAD/microRNA actions may provoke the best options for protection against TGFβ-induced adverse ischemic remodeling processes resulting in improved heart function after myocardial infarction. The gene discussed is TGFB1; the disease is myocardial infarction.